Overview

• Kamada Q3 revenue rises 13% to $47 mln, beating analyst expectations

• Adjusted EBITDA for Q3 increases 34% yr/yr, reflecting strong operational performance

• Company reiterates full-year 2025 revenue guidance of $178 mln-$182 mln

Outlook

• Kamada reiterates 2025 revenue guidance of $178 mln to $182 mln

• Company expects 2025 adjusted EBITDA of $40 mln to $44 mln

• Kamada to conduct interim futility analysis of InnovAATe trial this quarter

Result Drivers

• DIVERSE PORTFOLIO - Revenue growth driven by increased sales of GLASSIA in ex-U.S. markets and VARIZIG in U.S.

• SALES MIX - Improved sales mix and increased commercial scale boosted gross margins

• PLASMA OPERATIONS - Expansion of plasma collection operations supports revenue growth

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Kamada Ltd is $15.00, about 55.6% above its November 7 closing price of $6.66

• The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nGNX83lScz

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)